EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials

Guglielmo Beccuti, Fabio Bioletto, Mirko Parasiliti-Caprino, Andrea Benso, Ezio Ghigo, Alessandro Cicolin, Fabio Broglio

Current Obesity Reports · 08.10.2024 · 13 (4) · 739-742

DOI: 10.1007/s13679-024-00592-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Obesity Reports, online erschienen am 08.10.2024. Verfasst von Guglielmo Beccuti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy. guglielmo.beccuti@unito.it. Hauptthemen laut MEDLINE: Obesity, Sleep Apnea, Obstructive, Cardiovascular Diseases, Weight Loss. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Torino.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Commentary This commentary aims to offer a perspective on the effect of tirzepatide on hypoxic burden and provide indirect evidence of cardiovascular risk reduction after tirzepatide for the treatment of obstructive sleep apnea and obesity. It also discusses the role of tirzepatide-induced weight loss in the management of obstructive sleep apnea. Recent Findings. In the SURMOUNT-OSA phase 3 trials, tirzepatide, a new GIP/GLP-1 receptor co-agonist, reduced the apnea–hypopnea index, hypoxic burden, and body weight in adults with moderate-to-severe obstructive sleep apnea and obesity. The change in apnea–hypopnea index is clinically relevant, but its impact on cardiovascular mortality remains unclear. Conversely, hypoxic burden predicts cardiovascular mortality across populations independent of AHI. Summary We attempted to postulate the magnitude of cardiovascular benefits of tirzepatide based on the reduction in hypoxic burden. Tirzepatide treatment for obstructive sleep apnea and obesity seems to result in hypoxic burden values associated with a lower cardiovascular mortality rate and thus might attenuate the negative cardiovascular impact of hypoxic burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesitySleep Apnea, ObstructiveCardiovascular DiseasesWeight LossHumansHypoxiaClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Apnea–hypopnea indexCardiovascular riskHypoxic burdenObesitySleep apneaTirzepatide

Autor:innen und Institutionen

  • Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy. guglielmo.beccuti@unito.it.
  • Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy.
  • Department of Neurosciences "Rita Levi Montalcini", University of Turin, Turin, Italy.

Förderung

  • Università degli Studi di Torino

Zitieren

APA

Beccuti, G., Bioletto, F., Parasiliti-Caprino, M., Benso, A., Ghigo, E., Cicolin, A., & Broglio, F. (2024). Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials. Current Obesity Reports, 13(4), 739-742. https://doi.org/10.1007/s13679-024-00592-x

Vancouver

Beccuti G, Bioletto F, Parasiliti-Caprino M, Benso A, Ghigo E, Cicolin A, et al. Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials. Current Obesity Reports. 2024;13(4):739-742. doi:10.1007/s13679-024-00592-x

BibTeX
@article{Beccuti2024,
  author = {Beccuti, Guglielmo and Bioletto, Fabio and Parasiliti-Caprino, Mirko and Benso, Andrea and Ghigo, Ezio and Cicolin, Alessandro and Broglio, Fabio},
  title = {Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials},
  journal = {Current Obesity Reports},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {739--742},
  doi = {10.1007/s13679-024-00592-x}
}
Kostenlos starten →